Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paccis-RCT in Head and Neck Cancer
NCT01126216Phase 3Terminated
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jun 2010
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Primary endpoint: Disease Free Survival at 3 years. Started Jun 2010; status: terminated.
02
Drugs
paclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01126216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01126216.